Oklo stock tumbles as Financial Times scrutinizes valuation
Investing.com - RBC Capital upgraded Ovintiv Inc. (NYSE:OVV) from Sector Perform to Outperform while maintaining its price target of $55.00. According to InvestingPro data, the stock currently trades at $36.81, with analysts’ targets ranging from $42 to $67, suggesting significant upside potential.
The upgrade follows RBC’s update with the company, highlighting Ovintiv’s deep position in the Montney formation as an attractive avenue for energy investors seeking exposure to an emerging oil and condensate resource play in Canada.
RBC noted that Ovintiv has delivered impressive operational and financial performance over multiple quarters, along with strategic portfolio repositioning, though its relative valuation has not yet reflected these achievements.
The investment firm suggested that a better-defined shareholder returns profile, once Ovintiv reaches its $4.0 billion net debt target, could help improve the company’s market valuation. Enhanced reserve disclosure, potentially utilizing Canadian standards, was also mentioned as a possible catalyst.
RBC Capital additionally pointed to potential non-core asset sales as a strategy Ovintiv could pursue to accelerate its debt reduction goals.
In other recent news, Ovintiv Inc. reported second quarter earnings of $1.18 per share, surpassing analyst estimates of $0.98. The company also generated $1.01 billion in cash from operating activities and $392 million in non-GAAP free cash flow, following capital expenditures of $521 million. Ovintiv raised its full-year production guidance while lowering capital expenditure forecasts, with second quarter production averaging 615 thousand barrels of oil equivalent per day, exceeding its guidance across all product categories. Additionally, Ovintiv received regulatory approval from the Toronto Stock Exchange to renew its normal course issuer bid, allowing the purchase of up to 22,287,709 common shares. This share repurchase program will run from October 3, 2025, through October 2, 2026, representing 10 percent of the company’s public float as of late September 2025. In a separate development, Morgan Stanley downgraded Ovintiv from Overweight to Equalweight, citing valuation concerns after the company’s 11% outperformance against its peers. The firm also reduced its price target for Ovintiv to $48.00 from $52.00.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.